@article{Venables_Z-2021_28112,
title = {The impact of the COVID-19 pandemic on skin cancer incidence and treatment in England, 2020},
author = {Venables, Z. and Ahmed, S. and Bleiker, T. and Broggio, J. and Kwiatkowska, M. and Levell, N. and Millington, G. and Paley, L. and Payne, E. and Proby, C. and Vernon, S. and McPhail, S.},
month = {may},
year = {2021},
abstract = {The first UK national COVID-19 lockdown began 23rd March 2020. Immediately, almost all outpatient healthcare service requests temporarily focused exclusively on urgent referrals and two-week-wait urgent cancer referrals with restrictions due to staff sickness, redeployment and changing work environments. Additionally, patient anxiety regarding attending appointments and perceived overburdening of healthcare resources resulted in fewer presentations.2 Technological advancements have arisen from challenging circumstances. The National Cancer Registration and Analysis Service (NCRAS), England, has developed a Rapid Cancer Registration Dataset (RCRD). Utilising automated datafeeds, lag-time from diagnosis to registration is reduced from 18 to 4 months, however, data has not been quality assured to the same standards and completeness.4 We identify how the pandemic has affected skin cancer.},
journal = {British Journal of Dermatology},
publisher = {Wiley},
url = {https://doi.org/10.1111/bjd.20409},
}
